Renal failure results in the retention of metabolites which may arbitr
arily be grouped according to their molecular weight: low (<300 dalton
s molecular weight), middle (300-15,000 daltons), and high (>15,000 da
ltons). Opinion in respect to the relative importance of these groups
varies. Initially it was thought that small molecules were important.
In the mid-1970s, investigators identified the possible pathophysiolog
ical role of middle molecules. However, since positive identification
of such molecules was difficult, opinion has shifted back in favor of
small molecules, and little attention, with the exception of beta(2) m
icroglobulin, has been paid to middle molecules and their removal by h
emodialysis and related therapies. In this review current knowledge re
garding middle molecules identified as uremic toxins and their removal
by hemodialysis and associated therapies are discussed.